Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Chronic Lymphocytic Leukemia: Ibrutinib, Idelalisib, and Venetoclax
Crossref DOI link: https://doi.org/10.1007/s40262-017-0529-1
Published Online: 2017-03-25
Published Print: 2017-11
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Waldron, Madeline http://orcid.org/0000-0001-8113-5254
Winter, Allison
Hill, Brian T.
License valid from 2017-03-25